Tessa Therapeutics, a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced the close of a US$126 million Series A financing round.
Aspen Neuroscience, Inc., a private biotechnology company developing autologous cell therapies, including the first iPSC-derived autologous neuron replacement treatment for Parkinson’s disease, announced the close of its Series B funding round of $147.5 million.
RVAC Medicines, an emerging messenger RNA (mRNA) platform company incubated in Singapore by CBC Group, announced the completion of its series B financing, bringing the company’s total funds raised since its inception in June 2021 to US$140 million.
Digital Health Platform Doctor Anywhere Closes Series C Round to Deepen Southeast Asia Expansion
Full Press Release from Biofourmis
BOSTON, July 29, 2021
These 4 Singaporean companies are changing healthcare as we know it
MiRXES Secures US$77 Million Series C Funding To Accelerate Multi-Cancer Early Detection Pipeline With Overwhelming Investor Support
Nuevocor closes US$24M Series A Financing to Advance Novel Gene Therapies for Cardiomyopathies
MAY 26, 2021 – SINGAPORE & SAN CARLOS, Calif.–Engine Biosciences (“Engine”) today announced the successful completion of an oversubscribed $43 million Series A funding round. Engine identifies errors in the complex genetic codes of diseases, fixing them with precise therapeutic solutions.
© 2021- edbi. All rights reserved.
